These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 8165622)

  • 21. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
    van Griensven JM; Koster RW; Burggraaf J; Huisman LG; Kluft C; Kroon R; Schoemaker RC; Cohen AF
    Clin Pharmacol Ther; 1998 Jan; 63(1):39-47. PubMed ID: 9465840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
    Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
    J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
    Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
    Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant production of a hybrid plasminogen activator composed of surfactant protein B and low-molecular-weight urokinase.
    Ruppert C; Mahavadi P; Wygrecka M; Weaver TE; Magdolen V; Idell S; Preissner KT; Seeger W; Günther A; Markart P
    Thromb Haemost; 2008 Dec; 100(6):1185-92. PubMed ID: 19132247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Construction, expression and characterization of tissue-type plasminogen activator mutants.
    Liu S; Huang P; Huang C
    Sci China B; 1995 Nov; 38(11):1341-8. PubMed ID: 8745532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate.
    Wilson MJ; Ludowese C; Sinha AA; Estensen RD
    Prostate; 1996 Apr; 28(4):239-50. PubMed ID: 8602400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life.
    Zuckier LS; Chang CJ; Scharff MD; Morrison SL
    Cancer Res; 1998 Sep; 58(17):3905-8. PubMed ID: 9731501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simplified recombinant plasmin: production and functional comparison of a novel thrombolytic molecule with plasma-derived plasmin.
    Hunt JA; Petteway SR; Scuderi P; Novokhatny V
    Thromb Haemost; 2008 Sep; 100(3):413-9. PubMed ID: 18766256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasminogen activators: a comparison.
    Baruah DB; Dash RN; Chaudhari MR; Kadam SS
    Vascul Pharmacol; 2006 Jan; 44(1):1-9. PubMed ID: 16275118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis.
    Zaitsev S; Spitzer D; Murciano JC; Ding BS; Tliba S; Kowalska MA; Bdeir K; Kuo A; Stepanova V; Atkinson JP; Poncz M; Cines DB; Muzykantov VR
    J Pharmacol Exp Ther; 2010 Mar; 332(3):1022-31. PubMed ID: 19952305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of tissue plasminogen activators in rhesus monkeys: antibody formation and effects on blood level and enzymatic activity.
    Zwickl CM; Hughes BL; Piroozi KS; Smith HW; Wierda D
    Fundam Appl Toxicol; 1996 Apr; 30(2):243-54. PubMed ID: 8812272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Muscles as a possible source of plasminogen activators to the circulation.
    Menon IS
    J Assoc Physicians India; 1969 Mar; 17(3):141-5. PubMed ID: 5791200
    [No Abstract]   [Full Text] [Related]  

  • 36. The use of active centre acylation to control the pharmacokinetic profile of a recombinant chimaeric plasminogen activator.
    Wilson S; Cronk DW; Dodd I; Esmail AF; Kalindjian SB; McMurdo L; Browne MJ; Smith RA; Robinson JH
    Thromb Haemost; 1993 Dec; 70(6):984-8. PubMed ID: 8165622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Slow clearance of acylated, hybrid thrombolytic enzymes.
    Robinson JH; Dodd I; Esmail A; Ferres H; Nunn B
    Thromb Haemost; 1988 Jun; 59(3):421-5. PubMed ID: 3187931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interaction of a plasmin A-chain/t-PA B-chain hybrid enzyme with plasma inhibitors in vivo and in vitro.
    Wilson S; Chamberlain P; Dodd I; Esmail A; Robinson JH
    Thromb Haemost; 1990 Jun; 63(3):459-63. PubMed ID: 1698316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isolation, identification and pharmacokinetic properties of human tissue-type plasminogen activator species: possible localisation of a clearance recognition site.
    Dodd I; Nunn B; Robinson JH
    Thromb Haemost; 1988 Jun; 59(3):523-8. PubMed ID: 3142086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The fibrinolytic system and its activators].
    Seifried E
    Z Gesamte Inn Med; 1993; 48(6-7):272-82. PubMed ID: 8333223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.